compound 13a [PMID: 23639540]

Ligand id: 8155

Name: compound 13a [PMID: 23639540]

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 7
Hydrogen bond donors 1
Rotatable bonds 3
Topological polar surface area 71.34
Molecular weight 346.15
XLogP 1.65
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

Classification
Compound class Synthetic organic
IUPAC Name
4-[4-[3-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-6-yl]phenyl]morpholine
Database Links
BindingDB Ligand 50434751
ChEMBL Ligand CHEMBL2385579
GtoPdb PubChem SID 249565835
PubChem CID 60182393
Search Google for chemical match using the InChIKey WCDLCPLAAKUJNY-UHFFFAOYSA-N
Search Google for chemicals with the same backbone WCDLCPLAAKUJNY
Search UniChem for chemical match using the InChIKey WCDLCPLAAKUJNY-UHFFFAOYSA-N
Search UniChem for chemicals with the same backbone WCDLCPLAAKUJNY
Comments
The discovery of compound 13a is reported in [1], a medicinal chemistry study to identify selective bone morphogenetic protein receptor (BMP) inhibitors. Compound 13a inhibits the majority of Type I receptor serine/threonine kinases to a greater or lesser extent, but is most potent at ALK1 (ACVRL1) and ALK2 (ACVR1) which are activin receptor components, and ALK3 (BMPR1A) and ALK6 (BMPR1B) which are bone morphogenetic protein receptors. Compound 13a has its most potent inhibitory effect on TGFBR2 and VEGFR2, with approximately 25 times lower potency against BMPR2 and AMPK, where reported IC50s are more akin to those at the Type I receptor serine/threonine kinases [1].